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Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the 
third highest cause of cancer-related mortality in humans. Epigallocatechin-3-gallate 
(EGCG) has been shown to inhibit the metastatic activity of certain cancer cells. The aim 
of this study was to determine the effects and molecular mechanism(s) of action of 
EGCG in human HCC cells. A migration and invasion assay for the metastatic behavior 
of HCCLM6 cells was performed. The anti-metastatic effects of EGCG were investigated 
by RT-PCR and gelatin zymography. A total cellular protein profile was obtained using 2
-dimensional gel electrophoresis (2-DE), followed by matrix-assisted laser 
desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS) analyses of 
proteins with significant differences in expression following treatment with EGCG. The 
results revealed that EGCG induced apoptosis and inhibited the metastasis of HCCLM6 
cells. The anti-metastatic effects of EGCG were associated with the inhibition of matrix 
metalloproteinase (MMP)-2 and MMP-9 activity. The expression levels of far upstream 
element (FUSE) binding protein 1 (FUBP1), heat shock protein beta 1 (HSPB1), heat 
shock 60 kDa protein 1 (chaperonin) (CH60) and nucleophosmin (NPM) proteins, which 
are associated with metastasis, were significantly altered in the EGCG-treated HCCLM6 
cells. The data from the present study suggest that EGCG has potential as a therapeutic 
agent for the treatment of HCC.
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Terms and 
Conditions
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the 
third highest cause of cancer-related mortality (500,000 deaths annually) (1). HCC is a 
primary malignant tumor of the liver with high prevalence in Asia and Africa (2). There 
are a number of different therapies for the treatment of HCC, including percutaneous 
ethanol injection therapy (PEIT), transcatheter arterial chemoembolization (TACE), liver 
transplantation and surgical intervention. Of these, surgical intervention has been the 
most effective therapy for improving the survival of patients (3). Nevertheless, only a 
small subset of HCC patients increase their 5-year survival rate by surgical resection, 
primarily due to the high rate of metastasis and the expression of anti-apoptotic genes 
associated with HCC (4,5). Therefore, metastasis remains the major obstacle to the 
development of optimal treatment methods for HCC, and novel or adjunct therapeutic 
strategies are paramount to overcoming this obstacle.
Tea is the most widely consumed beverage worldwide; furthermore, green tea is sold 
on a large scale, in part, due to its chemotherapeutic value (6,7). Catechins constitute 
approximately 40% of the dry weight of green tea, and epigallocatechin-3-gallate 
(EGCG), a polyphenol, constitutes the highest percentage among the catechins (8–10).
EGCG has immense potential as a therapeutic agent for the treatment and/or 
prevention of cancer due to its low cost and high bioavailability (11). The anticancer role 
of EGCG has been investigated epidemiologically, inin vitro and in vivo models, as well 
as in clinical trials (12–14). In vitro studies have demonstrated the inhibitory effects of 
EGCG on cancer by suppressing metastasis (13,15,16). There is also a large body of 
evidence demonstrating the effects of EGCG on the migration ability of several human 
cancer cell lines by a multifactorial mechanism involving the downregulation of matrix 
metalloproteinases (MMPs) (15,17). Yet, the precise mechanisms of action of EGCG as 
an anticancer agent remain unknown.
To our knowledge, the potential effects of EGCG on HCCLM6, a human HCC metastatic 
cell line, have not been previously reported. Thus, in this study, we investigated the 
effects and molecular mechanisms of action of EGCG in HCCLM6 cells as a novel 
and/or adjunct therapeutic agent in the treatment of HCC.
Materials and methods
Antibodies and reagents
EGCG (≥98% purity), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) and gelatin were purchased from Sigma (St. Louis, MO, USA). The RNA PCR kit 
(AMV) was purchased from the Takara Biotechnology Co., Ltd. (Dalian, China). DMEM 
and fetal bovine serum (FBS) were purchased from Gibco (Grand Island, NY, USA). 
TRIzol was purchased from Invitrogen (Camarillo, CA, USA). The Pierce® SilverStain for 
Mass Spectrometry kit was purchased from Thermo Scientific (Rockford, IL, USA). 
Immobilized pH gradient (IPG) strips and the 2-D Cleanup kit were purchased from Bio-
Rad (Hercules, CA, USA). The BCA protein assay kit was purchased from KeyGen 
Biotech. Co. Ltd. (Nanjing, China), and 24-well, double-compartment Transwell plates 
were purchased from Corning Inc. (Lowell, MA, USA).
Cells and culture
HCCLM6 cells (ATCC, Manassas, VA, USA) were grown in DMEM supplemented with 
10% heat-inactivated FBS, 0.1% benzyl penicillin and streptomycin. Cells were 
maintained at 37°C in a humidified incubator with an atmosphere of 5% CO2.
Cell viability assay
HCCLM6 cells (6×103 cells/well) were plated in 96-well plates for 12 h. The cells were 
treated with various concentrations (0, 5, 10, 20, 30, 40, 50, 60, 80 or 100μg/ml) of EGCG 
and incubated for an additional 24 h. At the end of the treatment, the culture medium 
was replaced with fresh complete medium containing 0.5 mg/ml MTT and incubated at 
37°C for 4 h. Following incubation, the medium was discarded, and DMSO was added to 
the wells and gently agitated for 10 min. The absorbance was then measured at 490 
nm. The assay was repeated at least 3 times. The cell growth inhibition rates were 
calculated according to the following formula: inhibition rate (%) = (1 − mean 
absorbance of treated group/mean absorbance of untreated group) ×100%.
In vitro migration and invasion assays
The 24-well Transwell plates and 8.0 μm pore filter inserts (Corning Inc.) were used for 
the migration and invasion assays according to the standard Boyden Chamber protocol. 
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Briefly, HCCLM6 cells were seeded in a 6-well plate, and at 80% confluency, the cells 
were treated with 0, 5 or 10 μg/ml EGCG and incubated for 18 h. The cells were 
harvested, counted and diluted to 5×105/ml of viable cells in medium without FBS. The 
cell suspension (0.2 ml) was placed on top of the filter of the upper chamber, and 0.6 ml 
of complete medium was placed in the lower chamber. The filter insert was placed into 
the lower chamber and incubated for 18 h at 37°C. Non-migrated cells were removed 
from the top side of the filter by scrubbing with a cotton-tipped swab moistened with 
FBS-free medium. Migrated cells on the underside of the filter were fixed in 20% 
methanol for 20 min, stained with 0.1% crystal violet at 37°C for 30 min and then 
washed with PBS. The invasion assay was carried out as described above, except that 
the top side of the filter membrane was pre-coated with 50 μl of Matrigel (0.3 mg/50 μl; 
Bio-Rad) and incubated for 5 h at 37°C to allow the matrix to form a gel before seeding 
the cells onto it. Stained cells were photographed at ×200 magnification using a Nikon 
camera fitted to a Leica microscope (Leica Microsystems, Wetzlar, Germany).
Gelatin zymography
The HCCLM6 cells (1×105) were seeded in a 6-well plate. At 80% confluency, the cells 
were treated with 0, 5, 10 or 20 μg/ml EGCG and incubated for 18 h. Following 
incubation, the cells and medium were harvested and centrifuged (1,000 rpm for 5 min) 
to collect the supernatant. The supernatants from the samples were normalized to the 
cell number and electrophoresed on a 10% polyacrylamide gel containing 1 mg/ml 
gelatin at 4°C. Following electrophoresis, the gels were washed for 15 min in 2.5% 
Triton X-100 4 times at room temperature and then incubated for 24 h at 37°C in 
activation buffer (50 mM Tris-HCl, pH 7.5; 5 mM CaCl2; 10 mM NaCl; 10 mM ZnCl2). The 
gels were stained with 0.2% coomassie brilliant blue (Ameresco Co., Framingham, MA, 
USA) for 3 h and then destained in destaining buffer (30% methanol, 10% acetic acid) 
until the gelatinolytic activity of the MMPs are visible.
RT-PCR
The HCCLM6 cells (3×105) were seeded in 6-well plates until they reached 80% 
confluency. The cells were treated with 0, 5, 10 and 20 μg/ml EGCG or 0, 10 and 30 
μg/ml EGCG and incubated for 20 h. Total RNA was extracted with TRIzol according to 
the manufacturer’s instructions (Invitrogen). Semi-quantification and purity 
assessment were performed by optical density (OD) measurements at 260 and 280 nm. 
cDNA was synthesized from the total RNA using an RNA PCR kit (Takara Biotechnology 
Co., Ltd.). The primers were derived from human sequences (Table I), and the PCR 
conditions were optimized until the gene products were within the linear phase of PCR 
amplification. The PCR products were resolved on 1% (w/v) agarose gels containing 
ethidium bromide. The results were normalized to β-actin. The PCR conditions for each 
target gene (MMP-2, MMP-9 and β-actin) were as follows: 95°C for 5 min; 30 cycles of 
95°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec; 72°C for 10 min.
Table I
Primer sequences and PCR conditions.
Proteomic analysis of EGCG-treated cells
The HCCLM6 cells were plated as described above and treated with EGCG (0 or 20 
μg/ml). Total protein was extracted and pre-treated with the 2-D Cleanup kit (Bio-Rad). 
Isoelectrofocusing (IEF) was performed using 7 cm IPG strips (Bio-Rad) with an 
immobilized pH gradient from 3–10. The strips were rehydrated at room temperature 
for 16 h with 125 μl of swelling buffer (8 mol/l urea, 2% CHAPS, 2% IPG buffer, 0.3% 
DTT and a trace of bromophenol blue), which contained 45 μg of pre-treated proteins 
from either the EGCG-treated or untreated cells. IEF was performed at 200 V for 20 
min, 450 V for 15 min, 750 V for 15 min and 3,000 V for 2 h. Following IEF, the strips 
were immediately equilibrated with the equilibrium sample buffer (50 mmol/l Tris-HCl, 
pH 8.8; 6 mol/l urea; 30% glycerol; 2% SDS; and a trace of bromophenol blue) at room 
temperature for 30 min with gentle shaking. SDS-PAGE was performed using 12% SDS
-polyacrylamide gels. The strips were held in place with 0.5% agarose dissolved in SDS 
running buffer, and electrophoresis was then performed (5 mA for 20 min, 15 mA for 20 
min, 20 mA for 20 min, and 30 mA in 4°C for 2 h). The gels were stained with the Silver 
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Stain for Mass Spectrometry kit (Thermo Scientific) according to the manufacturer’s 
instructions. Image analysis was performed using the PDQuest system (Bio-Rad). The 
selected spots were excised, and the proteins were purified by an in-gel digestion with 
trypsin. The resulting peptides were subjected to analysis by matrix-assisted laser
desorption/ionization-time of flight mass spectrometry (MALDI-TOF/MS).
Statistical analysis
The results of all the experiments are expressed as the means ± SD. Statistical 
analyses were performed using SPSS 13.0 software. A P-value <0.05 was considered to 
indicate a statistically significant difference.
Results
Effects of EGCG on cell viability
To determine the effect of EGCG on HCC, HCCLM6 cells were treated with EGCG at 
concentrations varying between 5 and 100μg/ml. EGCG (10–100 μg/ml) significantly 
inhibited the growth of HCCLM6 cells in a dose-dependent manner (Fig. 1) (P<0.01). 
These results indicate that EGCG inhibits cell growth (or induces apoptosis) in the HCC 
cell line, HCCLM6.
Figure 1
Growth inhibition of HCCLM6 cells by epigallocatechin-3-gallate (EGCG). The data are presented 
as the means ± SD of 5 independent experiments. **P<0.01 compared with the control.
Effects of EGCG on cell migration and invasion
As indicated in Materials and methods, the 24-well Transwell membrane inserts had 
pores large enough to accommodate the migration (and/or the invasion) of single cells. 
The cells invading the underside of the 24-well Transwell membrane in these assays 
were fixed and stained (Fig. 2A and C). The cell migration analysis of HCCLM6 cells 
showed significantly lower (P<0.01) migration in the 5 and 10 μg/ml EGCG-treated cells 
compared with the untreated cells (Fig. 2B). The cell invasion analysis of HCCLM6 cells 
showed significantly lower (P<0.01) invasion in the 5 and 10 μg/ml EGCG-treated cells 
compared with the untreated cells (Fig. 2D).
Figure 2
(A) Effect of epigallocatechin-3-gallate (EGCG) on cell migration. EGCG was used at the 
following doses: (a) 0 μg/ml; (b) 5 μg/ml; (c) 10μg/ml. Images, ×200 magnification; scale bar, 200 
μm. (B) The data are presented as the means ± SD of 3 independent experiments. **P<0.01 
compared with the control. (C) Effect of EGCG on cell invasion. EGCG was used at the following 
doses: (a) 0μg/ml; (b) 5 μg/ml; (c) 10 μg/ml. Images, ×200 magnification; scale bar, 200 μm. (D) 
The data are presented as the means ± SD of 3 independent experiments. **P<0.01 compared with 
the control.
Effect of EGCG on MMP-2 and MMP-9 activity
Gelatin zymography analysis indicated that treatment with EGCG significantly inhibited 
the activity of MMP-2 and MMP-9 in the conditioned medium of HCCLM6 cells (Fig. 3A). 
The activity of MMP-2 and MMP-9 decreased in a dose-dependent manner with the 
increasing EGCG concentration (Fig. 3B and C, respectively).
Figure 3
(A) Comparative zymography analysis of matrix metalloproteinase (MMP)-2 and MMP-9. (B) 
Graphic representation of MMP-2 and (C) MMP-9; the data are expressed as the means ± SD of 3 
independent experiments. *P<0.05, **P<0.01, compared with the control. (D) RT-PCR analysis of 
MMP-2 and MMP-9. (E) MMP-2 and (F) MMP-9 mRNA expression normalized to β-actin; the 
data are expressed as the means ± SD of 3 independent experiments. *P<0.05, **P<0.01, compared 
with the control.
Effect of EGCG on MMP-2 and MMP-9 gene expression
To determine the effects of EGCG on the mRNA levels of MMP-2 and MMP-9 genes, the 
HCCLM6 cells (1×106 cells/ml) were maintained in culture with or without EGCG for 24 
h. Total RNA was isolated for RT-PCR as described above. As shown inFig. 3D, the 
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mRNA levels of MMP-2 and MMP-9 were downregulated in a dose-dependent manner 
by EGCG (Fig. 3E and F, respectively).
Proteomic analysis of EGCG-treated cells
The proteins from the EGCG-treated or untreated HCCLM6 cells were separated by 2-
dimensional gel electrophoresis (2-DE) according to their isoelectric points and 
molecular weights. The 2-DE gels represent the pattern of all the proteins in the 
untreated and EGCG-treated HCCLM6 cells (Fig. 4A). Of the proteins whose expression 
was significantly altered by EGCG treatment, 10 were selected (data not shown) and 
analyzed by MALDI-TOF/MS. Using bioinformatics mining with the MASCOT search 
engine (http://www.matrixscience.com/) and NCBI BLASTP 
(http://www.ncbi.nlm.nih.gov/blast), we determined significant functional differences 
(Table II) in 4 of these proteins (Fig. 4B).
Figure 4
(A) 2-dimensional gel electrophoresis of total proteins from HCCLM6 cells treated (a) without 
epigallocatechin-3-gallate (EGCG) or (b) with 30 μg/ml EGCG. The isoelectric point (pI) ranges 
from 3.5 to 9.5 (left to right panel), and the molecular mass ranges from 130 to 10 kDa (top to 
bottom). (B) Enlarged panels (1–4) of 4 proteins with significant functional differences in (a) 
untreated and (b) 30 μg/ml EGCG-treated HCCLM6 cells.
Table II
Characteristics of the 4 proteins with significant functional differences and their relative expression 
levels in HCCLM6 cells treated with EGCG.
Discussion
In this study, EGCG exhibited anticancer effects by clearly inhibiting the metastatic 
potential (migration and invasion) of HCCLM6 cells. MMP-2 and MMP-9 expression and 
enzyme activity correlated with the EGCG inhibition of metastasis, suggesting that 
EGCG prevents metastasis by inhibiting these enzymes (18). EGCG has been shown to 
inhibit tumor invasion and migration associated with MMPs in human breast cancer 
and pancreatic cancer cells (15,19). Metastasis, the spread of cancer in the body, is a 
major cause of mortality (19). Collagenase type IV (containing MMP-2 and MMP-9) is a 
key enzyme involved in tumor invasion and migration, as demonstrated by the anti-
metastatic effects of several collagenase inhibitors; some inhibitors have already been 
used in clinical trials (20). In our study, EGCG significantly inhibited HCCLM6 cell 
metastasis in a dose-dependent manner at both the mRNA expression and protein 
(enzyme) activity levels (Figs. 3and 4). These results suggest that EGCG inhibits the 
metastasis of HCCLM6 cells through the downregulation of MMPs.
To further understand the effects of EGCG on HCCLM6 cells and to identify potential 
novel therapeutic targets for HCC, the protein profiles of EGCG-treated and untreated 
cells were analyzed. We identified 4 proteins associated with cell growth and 
proliferation: far upstream element binding protein 1 (FUBP1), heat shock protein 
(HSP)B1, heat shock 60 kDa protein 1 (chaperonin) (CH60) and nucleophosmin (NPM) 
(Table II). FUBP1 is a DNA binding protein that activates the far upstream element of c-
Myc to stimulate its expression in HCC (21,22). FUBP1 functions as an ATP-dependent 
DNA helicase, which is overexpressed in soft tissue metastasis, and has been shown to 
be an important element in the progression of breast cancer metastasis (23). 
Therefore, FUBP1 may be an important component in the overall metastatic process of 
HCC. Panel 1 of Fig. 4B shows the decreased expression of FUBP1 protein following 
treatment with EGCG. EGCG anti-metastatic activity in HCCLM6 and in HCC, in general, 
may involve FUBP1 through a molecular mechanism similar to that proposed in other 
soft tissues (23).
HSPB1, also known as HSP27, belongs to the ubiquitous family of small HSPs. In panel 
2 of Fig. 4B, the enlarged 2-DE gel image shows a significant reduction in HSPB1 
expression following treatment with EGCG. In MDA-MB-231 breast cancer cells, 
increased HSPB1 expression has been shown to enhance metastasis through the 
upregulation of MMP-9 (24,25). HSP27 is a potent therapeutic target in breast cancer 
bone metastasis; the anti-metastatic agent, midazolium trans-imidazole dimethyl 
sulfoxide tetrachlororuthenate (NAMI-A), has been shown to decrease HSP27 protein 
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expression (26). In the present study, we hypothesized that treatment with EGCG may 
have decreased HSP27 expression by downregulating MMP-9 and reducing HCCLM6 
cancer cell metastasis (Table II andFig. 3).
NPM is a multifunctional protein that shuttles between the nucleoli and the cytoplasm, 
functioning as a chaperone for the nuclear export of ribosomal subunits (27,28). NPM 
shifts its location from the nucleolus to the nucleoplasm (NPM translocation) and 
accumulates if cells are exposed to actinomycin D, doxorubicin, or other DNA damaging 
agents (29,30). In our study, treatment with EGCG significantly increased NPM 
expression in HCCLM6 cells (Fig. 4B, panel 3). HeLa cells exposed to long-term and/or 
to high doses of actinomycin D (or other antibiotics with anticancer activity) have shown 
a significant accumulation of NPM in the nucleoplasm, which antagonizes both cell 
growth and RNA synthesis (29). EGCG may impair RNA synthesis, RNA processing and 
cell growth due to a loss of NPM binding targets in the nucleolus, which may cause it to 
accumulate in the nucleoplasm. The resulting loss of ribosomal assembly integrity may 
inhibit cellular growth (and/or metastasis) in HCCLM6 cells. In a recent study, 
increased NPM expression levels were suggested to enhance cellular transformation, 
antagonize the repression of cell adhesion genes and inhibit apoptosis mediated by the 
Myc-Miz1 complex if the alternate reading frame (Arf) tumor suppressor protein is 
present (31). These contradicting observations of NPM expression in cancer require 
further investigation to clearly define the ‘antagonistic’ function of this protein, either 
enhancing or reducing carcinogenesis and/or tumor progression.
CH60 has been associated with tumor metastasis by regulating tumor immunity (32,33). 
The overexpression of HSP60 has been shown to increase the migration and invasive 
potential of human pharyngeal squamous carcinoma cells (FADU cells) in vitro and in 
vivo (34). The enlargement of the 2-DE gel in panel 4 of Fig. 4B shows a significant loss 
of CH60 expression in the HCCLM6 cells following treatment with EGCG. CH60 may be a 
critical factor in the anti-metastatic activity of EGCG in HCCLM6 cells.
The present study demonstrates that EGCG inhibits HCCLM6 cell metastasis by 
inhibiting MMP-2, MMP-9, FUBP1, HSPB1 and CH60 expression and increasing NPM 
expression. However, further studies are required to investigate the specific anti-
metastatic mechanisms of action of EGCG and its effects on FUBP1, HSPB1, NPM and 
CH60 expression in cells in vitro and in vivo. Nevertheless, the data from the present 
study suggest that EGCG has potential as an anticancer agent in the treatment of HCC.
Abbreviations:
HCC hepatocellular carcinoma
EGCG epigallocatechin-3-gallate
2-DE 2-dimensional gel electrophoresis
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
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